Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for Israeli Healthcare Professionals only.

      pdd_banner_1
      pdd_banner_2
      pdd_banner_3
      pdd_banner_4
      Previous
      Next

      The efficacy and safety of 24-hour continuous levodopa-based therapy with PRODUODOPA were demonstrated in two phase 3 Studies.1-3

      12 weeks

      12-Week

      Pivotal phase 3, randomized, double-blind, double-dummy, active-controlled study evaluating the efficacy and safety of 24-hour daily continuous subcutaneous infusion of PRODUODOPA and compared with oral IR levodopa/carbidopa.2

      view more 2
      blue line
      52 weeks

      52-Week

      Phase 3, single-arm, open-label study evaluating the safety and efficacy of 24-hour daily exposure with a continuous subcutaneous infusion of PRODUODOPA. 3
       

      view more 2
      blue line
      Dose calculator
      AbbVie Care

      References

      1. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) prescribing information.
      2. Soileau MJ, et al. Lancet Neurol. 2022;21:1099–1109.
      3. Aldred J, et al. Neurol Ther. 2023 Aug 26. doi: 10.1007/5. s40120-023-00533.

      For Produodopa Prescribing Information click here

      IL-PRODD-240009. Date of preparation: July 2024.

      As part of ABBVIE CARE Produodopa patient support program,
      a professional call center is available: 

      Sunday through Thursday
      8:00-17:00

      052-8113004